Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 6—June 2023
Research

Early SARS-CoV-2 Reinfections Involving the Same or Different Genomic Lineages, Spain

Cristina Rodríguez-Grande, Agustín Estévez, Rosalía Palomino-Cabrera, Andrea Molero-Salinas, Daniel Peñas-Utrilla, Marta Herranz, Amadeo Sanz-Pérez, Luis Alcalá, Cristina Veintimilla, Pilar Catalán, Carolina Martínez-Laperche, Roberto Alonso, Patricia Muñoz, Laura Pérez-Lago1Comments to Author , Darío García de Viedma1Comments to Author , and on behalf of the Gregorio Marañón Microbiology-ID COVID 19 Study Group2
Author affiliations: Gregorio Marañón General University Hospital, Madrid, Spain (C. Rodríguez-Grande, A. Estévez, R. Palomino-Cabrera, A. Molero-Salinas, D. Peñas-Utrilla, M. Herranz, A. Sanz-Pérez, L. Alcalá, C. Veintimilla, P. Catalán, C. Martínez-Laperche, R. Alonso, P. Muñoz, L. Pérez-Lago, D. García de Viedma); Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid (C. Rodríguez-Grande, A. Estévez, R. Palomino-Cabrera, A. Molero-Salinas, D. Peñas-Utrilla, A. Sanz-Pérez, L. Pérez-Lago, D. García de Viedma); Universidad Complutense, Madrid (R. Alonso, P. Muñoz); Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Respiratorias-CIBERES, Madrid (R. Alonso, P. Muñoz, D. García de Viedma)

Main Article

Table 2

Clinical characteristics of patients with early SARS-CoV-2 reinfection or probable reinfection involving the same or different genomic lineages, Spain*

Pt. no. Age, y/sex Underlying conditions Illness severity, 1st/2nd episode† COVID-19 care required, 1st/
2nd episode COVID-19 treatment Vaccine schedule Inter-infection period, d PCR Ct, 1st/2nd episode Reason for PCR, 1st/
2nd episode SARS-CoV-2 variant, 
1st/2nd episode
Reinfections
1 29/M None Mild/mild N/N N N 37 24/22 Symp/symp AY.127/BA.1.1.1
2 12/M None Mild/mild N/N N N 34 30/19 Symp/symp AY.124/BA.1.1
3 8/F None Asymp/mild N/N N N 37 30/22 PE/symp B.1.617.2 Delta plus/BA.1.1
4 85/F HBP, DM, obesity Asymp/mild N/N N Complete, Pfizer 41 32/25 PP/PE BA.1.17/BA.1.1
5 27/F None Mild/asymp N/N N Complete, AstraZeneca/Pfizer 42 22/32 PP/PP BA.1.17/B.1.1.529
6 28/F None Asymp/mild N/N N Complete, Pfizer/ Moderna 27 32/16 PE/symp BA.1/BA.1.1
7 42/F None Mild/mild N/N N Incomplete, Pfizer 41 32/20 Symp/symp AY.122/BA.1.17
8 11/F None Asymp/ asymp N/N N N 22 30/27 PP/PP BA.2.36/BA.5.1
9 88/M COPD, ictus, heart disease, CKD Mod/asymp Hospital admission/N Steroids Complete, Pfizer 25 13/26 Symp/PP BA.5/BA.2
10 63/F HBP, systemic sclerosis Mild/asymp N/N N Incomplete, AstraZeneca 20 19/32 Symp/PP BA.5/BA.1.1
11
 83/M
 HBP, DM, ictus, heart disease
 Mod/asymp
 Hospital admission/N
 Steroids
 Complete, Pfizer
 27
 16/32
 Symp/PP
 BA.5.2/BA.5.1
Probable reinfections
23 74/F HBP, DM, heart disease NA/NA NA/NA NA Complete, Pfizer 21 31/16 NA/NA BA.2/BA.2
24 81/M HBP, DM, heart disease, CKD Mod/asymp Hospital admission/ hospital admission Steroids Complete, Pfizer 45 22/30 Symp/PP BA.1.1/BA.1.1
25 64/F HBP, CKD Mild/asymp Emergency/N N Incomplete, Pfizer 26 32/30 Symp/symp BA.1.17/BA.1.17
26 58/M HBP, DM Asymp/ asymp N/N N Complete, Pfizer 24 29/30 PP/PP BA.2/unassigned

*Asymp, asymptomatic; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HBP, high blood pressure; ICU, intensive care unit; NA, not available; PP, pre-procedure; PE, postexposure; symp, symptoms. †Severity of illness was defined according to the following criteria: mild, general unrest, cough, diarrhea, headache, fever, anosmia, dysgeusia, myalgia, rhinorrhea; Moderate, the above symptoms plus dyspnea, mild respiratory failure, or unilateral pneumonia; Severe, the above symptoms plus bilateral pneumonia or unilateral pneumonia with respiratory failure.

Main Article

1This senior authors contributed equally to this article.

2Additional members of the Gregorio Marañón Microbiology-ID COVID-19 Study Group who contributed data are listed at the end of this article.

Page created: April 17, 2023
Page updated: May 17, 2023
Page reviewed: May 17, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external